Notice of Pendency and Proposed Settlement of Derivative Action

Speed to IND has become the metric every biologics program is measured against. But bispecific and multispecific antibodies don’t follow a typical monoclonal antibody (mAb) development process, and neither do other difficult-to-express (DTE) proteins. Their structural complexity slows down exactly the step that speed depends on most: cell line development (CLD).Understanding and responding to the